Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204742 | 0.91 | ALDH1A1 (0.45) | GRM2PDK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4198518 | 0.88 | GRM2 (0.47) | GRM2PDK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2909628 | 0.88 | GRM2 (0.43) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157339 | 0.87 | MAPT (0.42) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157628 | 0.86 | GRM2 (0.41) | GRM2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1157260 | 0.84 | PDE4B (0.41) | GRM2KDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1157641 | 0.84 | PDE4A (0.53) | GRM2MAPTHTT | |
| SCHEMBL1157272 | 0.83 | MAPT (0.45) | GRM2PDK1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1157382 | 0.83 | PDE4A (0.42) | GRM2PDK1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1157560 | 0.83 | PDE4A (0.49) | PDK1ALDH1A1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | claimed |
| EP-1353907-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | claimed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002074726-A2 | ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-09-26 | — | — | WO | claimed |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2011-02-24 | — | — | US | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2007-04-05 | — | — | US | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | GRM2 3215/4885PDK1 720/4885HSD17B2 320/4885 |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | GRM2 3215/4885PDK1 720/4885HSD17B2 320/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | GRM2 3215/4885PDK1 720/4885HSD17B2 320/4885 |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | GRM2 3472/4885PDK1 418/4885HSD17B2 405/4885 |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | GRM2 3472/4885PDK1 418/4885HSD17B2 405/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | GRM2 3228/4885PDK1 788/4885HSD17B2 545/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | GRM2 3228/4885PDK1 788/4885HSD17B2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.